What they say:
A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for pulmonary arterial hypertension:Mangiferin, isolated from Mangifera Indica, inhibits the development of pulmonary arterial hypertension via down regulation of Notch3 and its target gene Hes5
Significance of the study:
Mangiferin, by increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thus, pharmacological formulations encompassing “Mangiferin or its analog, either alone or in combination with other drugs” may be used to treat pulmonary arterial hypertension.
Details of the research findings:
Idea formulated by : Dr. L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How Mangiferin inhibits Notch-3 expression
For purchase and payment details, you may reach us at firstname.lastname@example.org
# Research cooperation
Citation: Boominathan, L., Natural product therapy for pulmonary arterial hypertension:Mangiferin, isolated from Mangifera Indica, inhibits the development of pulmonary arterial hypertension via down regulation of Notch3 and its target gene Hes5, 11/November/2017, 11.59 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at email@example.com